(en) Reiko Watanabe, Ayako Ui, Shin-ichiro Kanno et Hideaki Ogiwara, « SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability », Cancer Research, vol. 74, no 9, , p. 2465–2475 (ISSN0008-5472 et 1538-7445, PMID24788099, DOI10.1158/0008-5472.CAN-13-3608, lire en ligne, consulté le )
mct.aacrjournals.org
(en) Rowan E. Miller, Rachel Brough, Ilirjana Bajrami et Chris T. Williamson, « Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib », Molecular Cancer Therapeutics, vol. 15, no 7, , p. 1472–1484 (ISSN1535-7163 et 1538-8514, PMID27364904, DOI10.1158/1535-7163.MCT-15-0554, lire en ligne, consulté le )
L. Ryan Baugh, Joanne C. Wen, Andrew A. Hill et Donna K. Slonim, « Synthetic lethal analysis of Caenorhabditis elegans posterior embryonic patterning genes identifies conserved genetic interactions », Genome Biology, vol. 6, , R45 (ISSN1474-760X, DOI10.1186/gb-2005-6-5-r45, lire en ligne, consulté le )
Nidhi Saini, Oleg Georgiev et Walter Schaffner, « The parkin Mutant Phenotype in the Fly Is Largely Rescued by Metal-Responsive Transcription Factor (MTF-1) ▿ », Molecular and Cellular Biology, vol. 31, no 10, , p. 2151–2161 (ISSN0270-7306, PMID21383066, PMCIDPMC3133352, DOI10.1128/MCB.05207-11, lire en ligne, consulté le )
(en) Renata Matuo, Fabrício G. Sousa, Daniele G. Soares et Diego Bonatto, « Saccharomyces cerevisiae as a model system to study the response to anticancer agents », Cancer Chemotherapy and Pharmacology, vol. 70, no 4, , p. 491–502 (ISSN0344-5704 et 1432-0843, DOI10.1007/s00280-012-1937-4, lire en ligne, consulté le )
(en) Douglas B. Wheeler, Steve N. Bailey, David A. Guertin et Anne E. Carpenter, « RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells », Nature Methods, vol. 1, no 2, , p. 127–132 (ISSN1548-7091, DOI10.1038/nmeth711, lire en ligne, consulté le )
(en) Hannah Farmer, Nuala McCabe, Christopher J. Lord et Andrew N. J. Tutt, « Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy », Nature, vol. 434, no 7035, , p. 917–921 (ISSN0028-0836, DOI10.1038/nature03445, lire en ligne, consulté le )
Shawn E. Yost, Erin N. Smith, Richard B. Schwab et Lei Bao, « Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens », Nucleic Acids Research, vol. 40, no 14, , e107 (ISSN0305-1048, PMID22492626, PMCIDPMC3413110, DOI10.1093/nar/gks299, lire en ligne, consulté le )
Denise Campisi Hegan, Latha Narayanan, Frank R. Jirik et Winfried Edelmann, « Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6 », Carcinogenesis, vol. 27, no 12, , p. 2402–2408 (ISSN0143-3334, PMID16728433, PMCIDPMC2612936, DOI10.1093/carcin/bgl079, lire en ligne, consulté le )
Ruben Agrelo, Wen-Hsing Cheng, Fernando Setien et Santiago Ropero, « Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer », Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no 23, , p. 8822–8827 (ISSN0027-8424, PMID16723399, PMCIDPMC1466544, DOI10.1073/pnas.0600645103, lire en ligne, consulté le )
(en) Joseph L. E. Bird, Katrin C. B. Jennert-Burston, Marcus A. Bachler et Penelope A. Mason, « Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease », Biogerontology, vol. 13, no 1, , p. 49–62 (ISSN1389-5729 et 1573-6768, DOI10.1007/s10522-011-9341-8, lire en ligne, consulté le )
KENTA MASUDA, KOUJI BANNO, MEGUMI YANOKURA et KOSUKE TSUJI, « Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells », Oncology Reports, vol. 28, no 4, , p. 1146–1152 (ISSN1021-335X, PMID22797812, PMCIDPMC3583574, DOI10.3892/or.2012.1912, lire en ligne, consulté le )
Kazunobu Futami, Motoki Takagi, Akira Shimamoto et Masanobu Sugimoto, « Increased Chemotherapeutic Activity of Camptothecin in Cancer Cells by siRNA-Induced Silencing of WRN Helicase », Biological and Pharmaceutical Bulletin, vol. 30, no 10, , p. 1958–1961 (DOI10.1248/bpb.30.1958, lire en ligne, consulté le )
(en) Kazunobu Futami, Yuichi Ishikawa, Makoto Goto et Yasuhiro Furuichi, « Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells », Cancer Science, vol. 99, no 5, , p. 843–848 (ISSN1349-7006, DOI10.1111/j.1349-7006.2008.00778.x, lire en ligne, consulté le )
Stephen Murata, Catherine Zhang, Nathan Finch et Kevin Zhang, « Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine », BioMed Research International, vol. 2016, (ISSN2314-6133, PMID27642590, PMCIDPMC5013223, DOI10.1155/2016/2346585, lire en ligne, consulté le )
(en) Reiko Watanabe, Ayako Ui, Shin-ichiro Kanno et Hideaki Ogiwara, « SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability », Cancer Research, vol. 74, no 9, , p. 2465–2475 (ISSN0008-5472 et 1538-7445, PMID24788099, DOI10.1158/0008-5472.CAN-13-3608, lire en ligne, consulté le )
Benjamin G. Biter, Katherine M. Aird, Azat Garipov et Hua Li, « Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal », Nature medicine, vol. 21, no 3, , p. 231–238 (ISSN1078-8956, PMID25686104, PMCIDPMC4352133, DOI10.1038/nm.3799, lire en ligne, consulté le )
Kimberly H. Kim, Woojin Kim, Thomas P. Howard et Francisca Vazquez, « SWI/SNF mutant cancers depend upon catalytic and non–catalytic activity of EZH2 », Nature medicine, vol. 21, no 12, , p. 1491–1496 (ISSN1078-8956, PMID26552009, PMCIDPMC4886303, DOI10.1038/nm.3968, lire en ligne, consulté le )
(en) Rowan E. Miller, Rachel Brough, Ilirjana Bajrami et Chris T. Williamson, « Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib », Molecular Cancer Therapeutics, vol. 15, no 7, , p. 1472–1484 (ISSN1535-7163 et 1538-8514, PMID27364904, DOI10.1158/1535-7163.MCT-15-0554, lire en ligne, consulté le )
B H Lok, A C Carley, B Tchang et S N Powell, « RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination », Oncogene, vol. 32, no 30, , p. 3552–3558 (DOI10.1038/onc.2012.391, lire en ligne)
Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner et Michelle Padget, « Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile », Blood, vol. 122, no 7, , p. 1293–1304 (ISSN0006-4971, PMID23836560, PMCIDPMC3744994, DOI10.1182/blood-2013-05-501072, lire en ligne, consulté le )
L. Ryan Baugh, Joanne C. Wen, Andrew A. Hill et Donna K. Slonim, « Synthetic lethal analysis of Caenorhabditis elegans posterior embryonic patterning genes identifies conserved genetic interactions », Genome Biology, vol. 6, , R45 (ISSN1474-760X, DOI10.1186/gb-2005-6-5-r45, lire en ligne, consulté le )
Prasenjit Dey, Joelle Baddour, Florian Muller et Chia Chin Wu, « Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer », Nature, vol. 542, no 7639, , p. 119–123 (DOI10.1038/nature21052, lire en ligne)
B H Lok, A C Carley, B Tchang et S N Powell, « RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination », Oncogene, vol. 32, no 30, , p. 3552–3558 (DOI10.1038/onc.2012.391, lire en ligne)
elsevier.com
linkinghub.elsevier.com
« Redirecting », sur linkinghub.elsevier.com (consulté le )
intechopen.com
(en) Carol Bernstein, Anil R., Valentine Nfonsam et Harris Bernstei, DNA Damage, DNA Repair and Cancer, InTech, (DOI10.5772/53919, lire en ligne)
(en) Carol Bernstein, Anil R., Valentine Nfonsam et Harris Bernstei, DNA Damage, DNA Repair and Cancer, InTech, (DOI10.5772/53919, lire en ligne)
L. Ryan Baugh, Joanne C. Wen, Andrew A. Hill et Donna K. Slonim, « Synthetic lethal analysis of Caenorhabditis elegans posterior embryonic patterning genes identifies conserved genetic interactions », Genome Biology, vol. 6, , R45 (ISSN1474-760X, DOI10.1186/gb-2005-6-5-r45, lire en ligne, consulté le )
Nidhi Saini, Oleg Georgiev et Walter Schaffner, « The parkin Mutant Phenotype in the Fly Is Largely Rescued by Metal-Responsive Transcription Factor (MTF-1) ▿ », Molecular and Cellular Biology, vol. 31, no 10, , p. 2151–2161 (ISSN0270-7306, PMID21383066, PMCIDPMC3133352, DOI10.1128/MCB.05207-11, lire en ligne, consulté le )
(en) Renata Matuo, Fabrício G. Sousa, Daniele G. Soares et Diego Bonatto, « Saccharomyces cerevisiae as a model system to study the response to anticancer agents », Cancer Chemotherapy and Pharmacology, vol. 70, no 4, , p. 491–502 (ISSN0344-5704 et 1432-0843, DOI10.1007/s00280-012-1937-4, lire en ligne, consulté le )
(en) Douglas B. Wheeler, Steve N. Bailey, David A. Guertin et Anne E. Carpenter, « RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells », Nature Methods, vol. 1, no 2, , p. 127–132 (ISSN1548-7091, DOI10.1038/nmeth711, lire en ligne, consulté le )
(en) Hannah Farmer, Nuala McCabe, Christopher J. Lord et Andrew N. J. Tutt, « Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy », Nature, vol. 434, no 7035, , p. 917–921 (ISSN0028-0836, DOI10.1038/nature03445, lire en ligne, consulté le )
Zhenyu Ji, Fang C. Mei, Pedro L. Lory et Scott R. Gilbertson, « Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer », Frontiers in bioscience : a journal and virtual library, vol. 14, , p. 2904–2910 (ISSN1093-9946, PMID19273243, PMCIDPMC2654594, lire en ligne, consulté le )
Shawn E. Yost, Erin N. Smith, Richard B. Schwab et Lei Bao, « Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens », Nucleic Acids Research, vol. 40, no 14, , e107 (ISSN0305-1048, PMID22492626, PMCIDPMC3413110, DOI10.1093/nar/gks299, lire en ligne, consulté le )
Latha Narayanan, James A. Fritzell, Sean M. Baker et R. Michael Liskay, « Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2 », Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no 7, , p. 3122–3127 (ISSN0027-8424, PMID9096356, lire en ligne, consulté le )
Denise Campisi Hegan, Latha Narayanan, Frank R. Jirik et Winfried Edelmann, « Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6 », Carcinogenesis, vol. 27, no 12, , p. 2402–2408 (ISSN0143-3334, PMID16728433, PMCIDPMC2612936, DOI10.1093/carcin/bgl079, lire en ligne, consulté le )
Ruben Agrelo, Wen-Hsing Cheng, Fernando Setien et Santiago Ropero, « Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer », Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no 23, , p. 8822–8827 (ISSN0027-8424, PMID16723399, PMCIDPMC1466544, DOI10.1073/pnas.0600645103, lire en ligne, consulté le )
(en) Joseph L. E. Bird, Katrin C. B. Jennert-Burston, Marcus A. Bachler et Penelope A. Mason, « Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease », Biogerontology, vol. 13, no 1, , p. 49–62 (ISSN1389-5729 et 1573-6768, DOI10.1007/s10522-011-9341-8, lire en ligne, consulté le )
KENTA MASUDA, KOUJI BANNO, MEGUMI YANOKURA et KOSUKE TSUJI, « Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells », Oncology Reports, vol. 28, no 4, , p. 1146–1152 (ISSN1021-335X, PMID22797812, PMCIDPMC3583574, DOI10.3892/or.2012.1912, lire en ligne, consulté le )
(en) Kazunobu Futami, Yuichi Ishikawa, Makoto Goto et Yasuhiro Furuichi, « Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells », Cancer Science, vol. 99, no 5, , p. 843–848 (ISSN1349-7006, DOI10.1111/j.1349-7006.2008.00778.x, lire en ligne, consulté le )
Stephen Murata, Catherine Zhang, Nathan Finch et Kevin Zhang, « Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine », BioMed Research International, vol. 2016, (ISSN2314-6133, PMID27642590, PMCIDPMC5013223, DOI10.1155/2016/2346585, lire en ligne, consulté le )
(en) Reiko Watanabe, Ayako Ui, Shin-ichiro Kanno et Hideaki Ogiwara, « SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability », Cancer Research, vol. 74, no 9, , p. 2465–2475 (ISSN0008-5472 et 1538-7445, PMID24788099, DOI10.1158/0008-5472.CAN-13-3608, lire en ligne, consulté le )
Benjamin G. Biter, Katherine M. Aird, Azat Garipov et Hua Li, « Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal », Nature medicine, vol. 21, no 3, , p. 231–238 (ISSN1078-8956, PMID25686104, PMCIDPMC4352133, DOI10.1038/nm.3799, lire en ligne, consulté le )
Kimberly H. Kim, Woojin Kim, Thomas P. Howard et Francisca Vazquez, « SWI/SNF mutant cancers depend upon catalytic and non–catalytic activity of EZH2 », Nature medicine, vol. 21, no 12, , p. 1491–1496 (ISSN1078-8956, PMID26552009, PMCIDPMC4886303, DOI10.1038/nm.3968, lire en ligne, consulté le )
(en) Rowan E. Miller, Rachel Brough, Ilirjana Bajrami et Chris T. Williamson, « Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib », Molecular Cancer Therapeutics, vol. 15, no 7, , p. 1472–1484 (ISSN1535-7163 et 1538-8514, PMID27364904, DOI10.1158/1535-7163.MCT-15-0554, lire en ligne, consulté le )
Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner et Michelle Padget, « Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile », Blood, vol. 122, no 7, , p. 1293–1304 (ISSN0006-4971, PMID23836560, PMCIDPMC3744994, DOI10.1182/blood-2013-05-501072, lire en ligne, consulté le )
Kazunobu Futami, Motoki Takagi, Akira Shimamoto et Masanobu Sugimoto, « Increased Chemotherapeutic Activity of Camptothecin in Cancer Cells by siRNA-Induced Silencing of WRN Helicase », Biological and Pharmaceutical Bulletin, vol. 30, no 10, , p. 1958–1961 (DOI10.1248/bpb.30.1958, lire en ligne, consulté le )
nature.com
(en) Douglas B. Wheeler, Steve N. Bailey, David A. Guertin et Anne E. Carpenter, « RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells », Nature Methods, vol. 1, no 2, , p. 127–132 (ISSN1548-7091, DOI10.1038/nmeth711, lire en ligne, consulté le )
(en) Hannah Farmer, Nuala McCabe, Christopher J. Lord et Andrew N. J. Tutt, « Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy », Nature, vol. 434, no 7035, , p. 917–921 (ISSN0028-0836, DOI10.1038/nature03445, lire en ligne, consulté le )
Nidhi Saini, Oleg Georgiev et Walter Schaffner, « The parkin Mutant Phenotype in the Fly Is Largely Rescued by Metal-Responsive Transcription Factor (MTF-1) ▿ », Molecular and Cellular Biology, vol. 31, no 10, , p. 2151–2161 (ISSN0270-7306, PMID21383066, PMCIDPMC3133352, DOI10.1128/MCB.05207-11, lire en ligne, consulté le )
Zhenyu Ji, Fang C. Mei, Pedro L. Lory et Scott R. Gilbertson, « Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer », Frontiers in bioscience : a journal and virtual library, vol. 14, , p. 2904–2910 (ISSN1093-9946, PMID19273243, PMCIDPMC2654594, lire en ligne, consulté le )
Shawn E. Yost, Erin N. Smith, Richard B. Schwab et Lei Bao, « Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens », Nucleic Acids Research, vol. 40, no 14, , e107 (ISSN0305-1048, PMID22492626, PMCIDPMC3413110, DOI10.1093/nar/gks299, lire en ligne, consulté le )
Latha Narayanan, James A. Fritzell, Sean M. Baker et R. Michael Liskay, « Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2 », Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no 7, , p. 3122–3127 (ISSN0027-8424, PMID9096356, lire en ligne, consulté le )
Denise Campisi Hegan, Latha Narayanan, Frank R. Jirik et Winfried Edelmann, « Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6 », Carcinogenesis, vol. 27, no 12, , p. 2402–2408 (ISSN0143-3334, PMID16728433, PMCIDPMC2612936, DOI10.1093/carcin/bgl079, lire en ligne, consulté le )
Ruben Agrelo, Wen-Hsing Cheng, Fernando Setien et Santiago Ropero, « Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer », Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no 23, , p. 8822–8827 (ISSN0027-8424, PMID16723399, PMCIDPMC1466544, DOI10.1073/pnas.0600645103, lire en ligne, consulté le )
KENTA MASUDA, KOUJI BANNO, MEGUMI YANOKURA et KOSUKE TSUJI, « Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells », Oncology Reports, vol. 28, no 4, , p. 1146–1152 (ISSN1021-335X, PMID22797812, PMCIDPMC3583574, DOI10.3892/or.2012.1912, lire en ligne, consulté le )
Stephen Murata, Catherine Zhang, Nathan Finch et Kevin Zhang, « Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine », BioMed Research International, vol. 2016, (ISSN2314-6133, PMID27642590, PMCIDPMC5013223, DOI10.1155/2016/2346585, lire en ligne, consulté le )
(en) Reiko Watanabe, Ayako Ui, Shin-ichiro Kanno et Hideaki Ogiwara, « SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability », Cancer Research, vol. 74, no 9, , p. 2465–2475 (ISSN0008-5472 et 1538-7445, PMID24788099, DOI10.1158/0008-5472.CAN-13-3608, lire en ligne, consulté le )
Benjamin G. Biter, Katherine M. Aird, Azat Garipov et Hua Li, « Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal », Nature medicine, vol. 21, no 3, , p. 231–238 (ISSN1078-8956, PMID25686104, PMCIDPMC4352133, DOI10.1038/nm.3799, lire en ligne, consulté le )
Kimberly H. Kim, Woojin Kim, Thomas P. Howard et Francisca Vazquez, « SWI/SNF mutant cancers depend upon catalytic and non–catalytic activity of EZH2 », Nature medicine, vol. 21, no 12, , p. 1491–1496 (ISSN1078-8956, PMID26552009, PMCIDPMC4886303, DOI10.1038/nm.3968, lire en ligne, consulté le )
(en) Rowan E. Miller, Rachel Brough, Ilirjana Bajrami et Chris T. Williamson, « Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib », Molecular Cancer Therapeutics, vol. 15, no 7, , p. 1472–1484 (ISSN1535-7163 et 1538-8514, PMID27364904, DOI10.1158/1535-7163.MCT-15-0554, lire en ligne, consulté le )
Kimberly Cramer-Morales, Margaret Nieborowska-Skorska, Kara Scheibner et Michelle Padget, « Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile », Blood, vol. 122, no 7, , p. 1293–1304 (ISSN0006-4971, PMID23836560, PMCIDPMC3744994, DOI10.1182/blood-2013-05-501072, lire en ligne, consulté le )
(en) Renata Matuo, Fabrício G. Sousa, Daniele G. Soares et Diego Bonatto, « Saccharomyces cerevisiae as a model system to study the response to anticancer agents », Cancer Chemotherapy and Pharmacology, vol. 70, no 4, , p. 491–502 (ISSN0344-5704 et 1432-0843, DOI10.1007/s00280-012-1937-4, lire en ligne, consulté le )
(en) Joseph L. E. Bird, Katrin C. B. Jennert-Burston, Marcus A. Bachler et Penelope A. Mason, « Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease », Biogerontology, vol. 13, no 1, , p. 49–62 (ISSN1389-5729 et 1573-6768, DOI10.1007/s10522-011-9341-8, lire en ligne, consulté le )
wiley.com
onlinelibrary.wiley.com
(en) Kazunobu Futami, Yuichi Ishikawa, Makoto Goto et Yasuhiro Furuichi, « Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells », Cancer Science, vol. 99, no 5, , p. 843–848 (ISSN1349-7006, DOI10.1111/j.1349-7006.2008.00778.x, lire en ligne, consulté le )